AveXis – First patient dosed in Phase 1 trial of AVXS-101 in SMA Type

CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) — AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering … Fortsätt läsa AveXis – First patient dosed in Phase 1 trial of AVXS-101 in SMA Type